AbCellera Biologics (ABCL) Prepaid Assets (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Prepaid Assets came in at $98.1 million in Q1 2026, up 3.59% YoY from $94.7 million in Q1 2025, and down 11.71% on a QoQ basis from $111.1 million in Q4 2025.
AbCellera Biologics (ABCL) Prepaid Assets (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of Prepaid Assets data on file, last reported at $98.1 million in Q1 2026.
- Quarterly Prepaid Assets rose 3.59% year-over-year to $98.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $98.1 million (up 3.59% YoY) and the FY2025 annual result came in at $111.1 million, up 65.49% from the prior year.
- Prepaid Assets fell to $98.1 million in Q1 2026, from $111.1 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $133.0 million in Q3 2025 to a low of $28.9 million in Q1 2022.
- A 5-year average of $73.3 million and a median of $67.1 million in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets soared 600.81% — and 2024, when it slumped 43.01%.
- Tracing ABCL's Prepaid Assets over 5 years: stood at $75.4 million in 2022, then slipped by 25.99% to $55.8 million in 2023, then climbed by 20.3% to $67.1 million in 2024, then jumped by 65.49% to $111.1 million in 2025, then dropped by 11.71% to $98.1 million in 2026.
- The last three Prepaid Assets figures came in at $98.1 million (Q1 2026), $111.1 million (Q4 2025), and $133.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 95.53 Mn |
| Mar 31, 2026 | 98.10 Mn |
| Dec 31, 2025 | 111.11 Mn |
| Sep 30, 2025 | 133.01 Mn |
| Jun 30, 2025 | 116.76 Mn |
| Mar 31, 2025 | 94.71 Mn |
| Dec 31, 2024 | 67.14 Mn |
| Sep 30, 2024 | 43.37 Mn |
| Jun 30, 2024 | 40.06 Mn |
| Mar 31, 2024 | 56.51 Mn |
| Dec 31, 2023 | 55.81 Mn |
| Sep 30, 2023 | 71.23 Mn |
| Jun 30, 2023 | 64.36 Mn |
| Mar 31, 2023 | 99.16 Mn |
| Dec 31, 2022 | 75.41 Mn |
| Sep 30, 2022 | 46.50 Mn |
| Jun 30, 2022 | 43.89 Mn |
| Mar 31, 2022 | 28.92 Mn |
| Dec 31, 2021 | 21.25 Mn |
| Sep 30, 2021 | 6.64 Mn |